Compare Cassava Sciences Inc (FLNA) vs SOLAI Limited (SLAI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs SOLAI Limited — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while SOLAI Limited trades at $2.91 (market cap $14.13M). The key difference: Cassava Sciences Inc is far larger — about 3.8× SOLAI Limited's market cap. Which is the better fit depends on your goals.
| FLNA | SLAI | |
|---|---|---|
Market Cap | $53.14M | $14.13M |
Sector | Health | Technology |
52-Week High | $4.64 | $30.66 |
52-Week Low | $1.09 | $2.74 |
Enterprise Value | -$33.43M | $13.77M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
SLAI trades at $3.10, down 1.27% today, with a bearish technical signal from moving averages. The company reported a net loss of $33.88 million in 2025, with negative profit margins and ROE of -114.71%. Recent news includes a reverse stock split and a going-private proposal, while the sole analyst coverage is a Hold rating.
The outlook remains challenged by persistent losses and NYSE listing concerns. Investment opportunity hinges on successful execution of AI product launches and potential privatization, but risks include weak fundamentals and high financial distress.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About SOLAI Limited
SOLAI focuses on providing innovative AI-driven software solutions. The company leverages artificial intelligence to enhance digital experiences and optimize business processes for various industries.
Read more on SLAI →
